Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

Background: The effectiveness of apatinib and cabozantinib for the treatment of radioactive iodine–refractory differentiated thyroid cancer (RAIR-DTC) has been demonstrated recently. We aimed to evaluate the cost-effectiveness of these treatments from the Chinese healthcare system perspective. Metho...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Bo, Ma, Wenbiao, Pan, Hongshuai, Shi, Yang, Zhang, Huan, Xing, Shenghai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280160/
https://www.ncbi.nlm.nih.gov/pubmed/35847009
http://dx.doi.org/10.3389/fphar.2022.860615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280160/
https://www.ncbi.nlm.nih.gov/pubmed/35847009
http://dx.doi.org/10.3389/fphar.2022.860615

Ejemplares similares